Cerba Research

Unveiling the Oncology Journey:

Highlighting cutting-edge capabilities



Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®.

Notably, Cerba Research has played a pivotal role in the approval of 24 innovative oncology drugs for indications like multiple myeloma and breast cancer, as well as 3 cell and gene therapies.

Our Oncology Highlights

- **29,400+** Patients screened
- **23,300+** Patients randomized
- **~200** Oncology trials since 2018
- **~75%** Trials include specialty testing
- **24** Approved oncology medications

Oncology Overview



Clinical Trial Phases Overview



Cerba Research

Sponsor Type

Oncology clinical trials experience in 2023 – facts and figures



Indications By Solid Tumor*

2%
Glioblastoma

4%
Pancreatic Cancer

4%
Ovarian Cancer

6%
Colorectal Cancer

7%
Non-Small Cell Lung Cancer

9%
Prostate Cancer

14%
Breast Cancer

18%
Bundled Rare Tumor Types

38%
Solid Tumors**

*% Solid Tumor Trials By Indication
**Solid tumor trials are phase I-FIH for the most part which have no specific indication.

Cerba Research

Sponsor Type

1% Other/NPO

18% Large pharma

9% Small–Midsize Pharma

72% Biotech/ Biopharma

~200 Oncology trials since 2018

OncoSign 600+ (638 Genes)

More Panels Available On Demand

Our comprehensive solid tumor profiling assay, which is CE–marked, supports identification of DNA and RNA variants implicated in various solid tumor types. This comprehensive tumor genomic profiling assay evaluates 638 genes, including 20 fusions, for multiple variant types, including TMB, MSI & HRD. It covers mutations with established, emerging & exploratory value across lung, ovarian, breast, colon, melanoma, bladder, GIST and more. It is performed on FFPE with 2 tubes containing 5 curls of 5 u thickness.

Turnaround Time

- 15 Days

Services Included

- DNA/RNA extraction
- QC
- Library prep Sequencing
- Alignment
- Data analysis, including SNVs, MNVs, INDELs, CNVs, gene fusions, etc
- TMB, MSI, HRD

Deliverables

- Data analysis reports

Cerba Research

A Cerba Research capabilities snapshot for your Oncology Trial

Cell

- FCM, Cytek Aurora immunophenotyping (including intra-cell markers)
- Receptor occupancy
- MRD detection
- CAR T cell enumeration
- CAR T cell phenotyping
- Intracellular cytokine detection
- PBMC isolation
- BMMC isolation
- Optical genome mapping, our next generation cytogenetic
- PK/ADA/Nab

Tissue

- Multiplex/simplex IHC
- 250+ biomarkers/protocols
- Full histopath service
- Halo®, Visiopharm®, AIForia®
- Board certified pathologists
- Large biobank
- Strong immuno-oncology simplex & multiplex panels
- Spatial analysis of the tumor microenvironment
- NanoString®, FISH, ISH

DNA/RNA

- NGS, oncopanels, broad panels, custom panels
- RNA seq
- Single-gene
- ctDNA-based panels
- ddPCR, qPCR
- Whole exome/whole genome
- HLA typing
- TCR/BCR seq
- NanoString®
- SNP-array
- DNA/RNA extraction
- Streck cell-free DNA BCT®
- PaxGene®, Qiamp kits

Protein

- Multiplex cytokine profiling (37-plex)
- 50+ ligand binding assays
- ELISA
- ELLA
- MSD
- ELISpot
- PK/ADA/Nab

Routine/Safety

- Coagulation
- Hematology
- Biochemistry
- Urinalysis
- Pregnancy test
- COVID test
- Serology
- Thyroid function



Acronyms

ADA: Antibody-drug antibody, ADC: Antibody-drug conjugate, BCR: B cell receptor, BMMC: Bone marrow mononuclear cells, CAR T: Chimeric antigen receptor T cell, CGT: Cell and gene therapy, CNV: Copy number variation, ddPCR: Droplet digital polymerase chain reaction, DNA: Deoxyribonucleic acid, ELISA: Enzyme-linked immunosorbent assay, FCM: Flow cytometry, FFPE: Formalin-fixed paraffin-embedded, FISH: Fluorescence in situ hybridization, GIST: Gastrointestinal stromal tumor, HLA: Human leukocyte antigens, HRD: Homologous recombination deficiency, FIH: First in human, IHC: Immunohistochemistry, INDEL: Insertion-deletion, ISH: In situ hybridization, mAb: Monoclonal antibodies, MRD: Minimal residual disease, MSD: Mesoscale discovery, MSI: Microsatellite instability, Nab: Neutralizing antibody, NC: Not confirmed, PBMC: Peripheral blood mononuclear cells, PK: Pharmacokinetics, QC: Quality control, qPCR: Quantitative polymerase chain reaction, RNA: Ribonucleic acid, SNP: Single nucleotide polymorphism, SNV: Single nucleotide variant, TCR: T cell receptor, TMB: Tumor mutational burden.